Detalles de la búsqueda
1.
Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.
Antimicrob Agents Chemother
; 58(7): 3714-9, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24752275
2.
Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.
Antimicrob Agents Chemother
; 58(7): 3708-13, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24752276
3.
A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.
J Aerosol Med Pulm Drug Deliv
; 27(6): 441-8, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24383962
4.
Regulatory aspects of Phase 3 endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.
J Aerosol Med Pulm Drug Deliv
; 25(4): 198-203, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22857271
5.
Inhaled lidocaine for the treatment of asthma: lack of efficacy in two double-blind, randomized, placebo-controlled clinical studies.
J Aerosol Med Pulm Drug Deliv
; 23(6): 381-8, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20958143
Resultados
1 -
5
de 5
1
Próxima >
>>